Here, we show the superior efficacy of SGRP-secreting CAR T cells in treating EGFRvIII-mosaic GBM and CD19+ lymphoma, offering an approach to target solid tumors heavily infiltrated by immunosuppressive innate immune cells. Here, CD19 is linked to lymphoma.